Formulation and Optimization of Avanafil Biodegradable Polymeric Nanoparticles: A Single-Dose Clinical Pharmacokinetic Evaluation.

Box–Behnken biodegradable polymers clinical pharmacokinetics drug delivery nanoparticles

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
26 Jun 2020
Historique:
received: 06 06 2020
revised: 22 06 2020
accepted: 23 06 2020
entrez: 2 7 2020
pubmed: 2 7 2020
medline: 2 7 2020
Statut: epublish

Résumé

Avanafil (AVA) is a second-generation phosphodiesterase-5 (PDE5) inhibitor. AVA shows high selectivity to penile tissues and fast absorption, but has a bioavailability of about 36%. The aim was to formulate and optimize AVA-biodegradable nanoparticles (NPs) to enhance AVA bioavailability. To assess the impact of variables, the Box-Behnken design was utilized to investigate and optimize the formulation process variables: the AVA:poly (lactic-co-glycolic acid) (PLGA) ratio (

Identifiants

pubmed: 32604853
pii: pharmaceutics12060596
doi: 10.3390/pharmaceutics12060596
pmc: PMC7356025
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : King Abdulaziz University
ID : G-222-249-1440

Références

Int J Pharm. 2016 Feb 29;499(1-2):236-246
pubmed: 26746800
J Agric Food Chem. 2011 Sep 14;59(17):9280-9
pubmed: 21797282
Expert Opin Investig Drugs. 2008 Jun;17(6):855-64
pubmed: 18491987
J Control Release. 2004 Sep 30;99(2):271-80
pubmed: 15380636
J Pharm Sci. 1999 Apr;88(4):454-8
pubmed: 10187757
J Control Release. 2006 Dec 1;116(3):337-45
pubmed: 17097180
Pharm Dev Technol. 2016 Mar;21(2):172-9
pubmed: 26794936
Int J Mol Sci. 2014 Dec 22;15(12):23909-23
pubmed: 25535080
Int J Nanomedicine. 2019 Sep 12;14:7461-7473
pubmed: 31686817
J Microencapsul. 2016 May;33(3):229-38
pubmed: 26886073
Eur J Pharm Biopharm. 2007 Jun;66(3):488-92
pubmed: 17433641
J Biomed Mater Res. 1998 Oct;42(1):45-54
pubmed: 9740006
Res Pharm Sci. 2017 Feb;12(1):1-14
pubmed: 28255308
Pharmaceutics. 2020 May 27;12(6):
pubmed: 32471119
Pharm Res. 1987 Dec;4(6):465-71
pubmed: 3508558
Clin Ther. 2010 Jun;32(6):1178-87
pubmed: 20637970
Eur J Pharm Sci. 2009 Mar 2;36(4-5):580-90
pubmed: 19135530
Sci Rep. 2018 Oct 25;8(1):15802
pubmed: 30361675
J Control Release. 2001 Mar 12;71(1):53-69
pubmed: 11245908
Pharmaceutics. 2019 Jan 01;11(1):
pubmed: 30609647
J Control Release. 2000 Sep 3;68(3):419-31
pubmed: 10974396
Int J Mol Sci. 2019 Nov 18;20(22):
pubmed: 31752085
Int J Pharm. 2015 May 15;485(1-2):329-40
pubmed: 25796122
Drugs Aging. 2013 Oct;30(10):853-62
pubmed: 23955441
EPMA J. 2010 Mar;1(1):164-209
pubmed: 23199049
Biomatter. 2013 Apr-Jun;3(2):
pubmed: 23719178
Ther Clin Risk Manag. 2014 Aug 27;10:701-11
pubmed: 25210457
Vasc Health Risk Manag. 2012;8:517-23
pubmed: 22973106
Iran J Pharm Res. 2019 Winter;18(1):156-167
pubmed: 31089352
Eur J Pharm Sci. 2017 Mar 30;100:262-272
pubmed: 28126560
J Biomed Mater Res B Appl Biomater. 2017 Aug;105(6):1692-1716
pubmed: 27098357
J Microencapsul. 2002 Jul-Aug;19(4):451-61
pubmed: 12396382
Iran J Pharm Res. 2014 Summer;13(3):819-33
pubmed: 25276182
J Colloid Interface Sci. 2009 Jun 1;334(1):75-81
pubmed: 19380149
Chem Pharm Bull (Tokyo). 1988 Mar;36(3):1095-103
pubmed: 3136939
J Pharm Sci. 1999 Jan;88(1):126-30
pubmed: 9874713
Artif Cells Nanomed Biotechnol. 2017 Mar;45(2):313-320
pubmed: 26900050
Pharm Res. 1993 Mar;10(3):362-8
pubmed: 8464808
J Control Release. 2014 Jun 10;183:77-86
pubmed: 24675377
J Pharm Sci. 1998 Oct;87(10):1229-34
pubmed: 9758682
Drug Des Devel Ther. 2016 Apr 05;10:1323-33
pubmed: 27103786
Int J Nanomedicine. 2017 Oct 05;12:7291-7309
pubmed: 29042776
J Control Release. 2002 Oct 4;83(2):273-286
pubmed: 12363453
Adv Pharm Bull. 2018 Mar;8(1):77-84
pubmed: 29670842
Front Pharmacol. 2016 Jun 28;7:185
pubmed: 27445821
Pharm Res. 2014 Aug;31(8):1967-77
pubmed: 24549821
J Biomed Mater Res B Appl Biomater. 2003 Aug 15;66(2):559-66
pubmed: 12861608
Pharmaceutics. 2020 Apr 11;12(4):
pubmed: 32290412
Drug Des Devel Ther. 2016 Oct 19;8:3407-3413
pubmed: 27799745

Auteurs

Hibah M Aldawsari (HM)

Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.

Usama A Fahmy (UA)

Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.

Fathy Abd-Allah (F)

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo 11865, Egypt.

Osama A A Ahmed (OAA)

Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Department of Pharmaceutics & Industrial Pharmacy, Faculty of Pharmacy, Minia University, Minia 61111, Egypt.

Classifications MeSH